Efficacy of Risankizumab across distinct PsA phenotypes identified with machine learning analytics using data from biologic DMARD-Naïve patients in two phase 3 clinical trials
Source check: Source checked. Not independent scientific confirmation.
Finding: Unsupervised finite-mixture analysis identifies five PsA phenotypes in 1,119 phase-3-trial participants and compares risankizumab outcomes by phenotype; this is a specific post-hoc treatment-response analysis. Publisher citation metadata lists 2026/12; the checked first result-bearing source version is dated 2025-11-29.
Technology: An unsupervised finite-mixture model identifies psoriatic-arthritis phenotypes for post-hoc comparison of risankizumab outcomes.
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
- AI contribution
- An unsupervised finite-mixture model identifies psoriatic-arthritis phenotypes for post-hoc comparison of risankizumab outcomes.
- Test and result
- Unsupervised finite-mixture analysis identifies five PsA phenotypes in 1,119 phase-3-trial participants and compares risankizumab outcomes by phenotype; this is a specific post-hoc treatment-response analysis.
- Limitation / still unknown
- notypes in 1,119 phase-3-trial participants and compares risankizumab outcomes by phenotype; this is a specific post-hoc treatment-response analysis.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://link.springer.com/article/10.1186/s13075-025-03670-0
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 2/5 · Validation 2/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.